Organ-on-Chip Market 2020-2026
|出版商||Orion Market Research Pvt Ltd||商品編碼||1008112|
|全球器官芯片市場預測（2020-2026） Organ-on-Chip Market 2020-2026|
|出版日期: 2021年05月04日||內容資訊: 英文||
在預測期內，全球器官芯片市場預計將以約 34.1% 的複合年增長率增長。生物功能芯片 (OoC)，也稱為微生理系統 (MPS) 或 "組織芯片" ，可以在藥物發現和開發過程的多個階段提供有用的信息。這些創新設備不僅可以洞察正常的人體器官功能和疾病的病理生理學，還可以更準確地預測研究藥物在人體中的安全性和有效性。用於改進藥物發現和更好地預測器官毒性疾病的人體組織芯片的開發是市場的主要驅動力。除此之外，產品發佈、技術進步和提高公眾意識的努力也是推動市場增長的因素。例如，2020 年 10 月，BioVox 為荷蘭初創公司 Bi/ond 啟動了一項提高認識計劃，以通過推廣生物功能芯片戰略來提高認識。通過這種認知策略，BioVocx 旨在促進器官芯片技術的採用，改進體外研究模型，並減少動物試驗。然而，生物功能芯片模型的高成本以及與生物功能芯片技術相關的技術問題是市場增長的障礙。在預測期內，對個性化癌症治療的需求增加以及對生物功能芯片模型的研究和資金增加，預計將為市場創造充足的機會。
COVID-19 對器官芯片市場的影響：自 2019 年 12 月以來，COVID-19 大流行的爆發對生物功能芯片市場產生了積極影響。生物功能芯片的主要行業應用包括藥物發現和毒理學研究。 COVID-19 在這些地區的主要經濟體（如美國、中國和日本）的爆發對市場增長產生了積極影響。科學家和研究人員在藥物發現中使用生物功能芯片進行疫苗接種，以控制 COIVID-19 在世界人口中的傳播，並瞭解對 SARS-CoV-2 的免疫反應。 2020 年 10 月，美國食品和藥物管理局 (FDA) 使用芯片上的器官模型來檢查預防 COVID-19 感染和其他過程的機制。根據一項聯合研究協議，FDA 在此過程中使用 Emulate Inc 的生物功能芯片模型。在 COVID-19 大流行期間，越來越多地使用芯片上的梯級（肺）來研究和開發改善病毒引起的肺部感染的藥物。這些因素對市場增長產生積極影響。
Global Organ-on-Chip Market Size, Share & Trends Analysis Report By Type (Lung-on-Chip, Heart-on-Chip, Kidney-on-Chip, and Others) By Application (Drug Discovery, Toxicology Research, and Others) By End-User (Pharmaceutical & Biotechnology Industry and Academic & Research Institutes) Forecast 2021-2027
The global market for organ-on-chip is projected to have a CAGR of around 34.1% during the forecast period. Organs-on-chips (OoCs), also known as microphysiological systems (MPS) or 'tissue chips' has the potential to be informative at multiple stages of the drug discovery and development process. These innovative devices could provide insights into normal human organ function and disease pathophysiology, as well as more accurately predict the safety and efficacy of investigational drugs in humans. The major driver for the market includes the development of human tissue chips for improvement in drug discovery and improvement in the prediction of organ toxicity liabilities. Apart from this, the product launches and advancement in technology, and initiatives to promote awareness among populations are the other factors that are driving the growth of the market. For instance, in October 2020, BioVox started an awareness program for Dutch startup Bi/ond to raise awareness by promoting organ-on-chip initiatives. Through this awareness initiative, BioVocx aims to promote the adoption of Organ-on-Chip technology to improve in vitro research models and reduce animal testing. However, the high cost of organ-on-chip models and technical difficulties linked with organ-on-chip technology acts as a barrier to the growth of the market. Whereas the demand for personalized cancer treatment and growing research and funding for organ-on-chip models will create an ample opportunity for the market during the forecast period.
COVID-19 Impact on Organ-on-Chip market: The organ-on-chip market is positively affected by the outbreak of the COVID-19 pandemic since December 2019. The key industry application of organ-on-chip includes drug discovery, toxicology research, and others that rely on the region such as North America and Asia-Pacific. The outbreak of COVID-19 in the major economies of these regions such as the US and China, Japan has positively impacted the market growth. To curb the spreading of COIVID-19 among the world's population the scientists and researchers have been using organ-on-chips for drug discovery for the vaccination and to understand immune responses against SARS-CoV-2. In Oct 2020, The Food and Drug Administration had used organ-on-chip models to test mechanisms for preventing COVID-19 infections, and other processes. The FDA used Emulate Inc's organ-on-chip models for this process under a cooperative research agreement. During the COVID-19 pandemic, the use of lung-on-chips was increased for the research and developments of drugs to recover the lung infection caused by the virus. These factors affected the growth of the market positively.
The global organ-on-chip market is segmented based on type, application, and end-user. On the basis of organ type, the organ-on-chip market is segmented into lung-on-chip, heart-on-chip, kidney-on-chip, and others. Among these types, the heart-on-chip type has a higher potential to grow during the forecast period. Due to the rising prevalence of cardiovascular disease (CVD), heart-on-chip are microdevices are primarily used for heart disease research, cardiotoxicity screening, drug target discovery, and drug efficacy testing. Similarly, based on application, the market is further categorized into drug discovery, toxicology research, and others. Based on end-user, the market is divided into the pharmaceutical & biotechnology industry, academic & research institutes.
Global Organ-on-chip Market Share by Application, 2020 (%)
Source: OMR global
Drug discovery application holds the Major Share in the global organ-on-chip market
Among application, the drug discovery segment projected to have the largest share in the market in 2020 and is expected to continue its dominance during the forecast period. The rising application of organ-on-chip devices in the drug development pipeline from early drug discovery to preclinical screening, testing, and translation of new drugs results in the growth of the market. Organ-on-chip in drug discovery reduces the drug failure rate. Many pharmaceutical companies have been searching for efficient drug discovery methods, Organ-on-a-Chip can provide them with cutting-edge technology that can emulate the physiological environment and functionality of human organs on a chip for disease modelling and drug testing. Thus, the use of organ-on-chip in drug discovery application to discover an effective solution to eliminating the effect of the disease can drive the demand for these chips, that will further drive the overall market growth.
Geographically, the global organ-on-chip market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, ASEAN and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, Asia-Pacific is anticipated to witness a significant growth rate during the forecast period due to growing awareness of and government initiatives for the adoption of innovative healthcare technologies and the development of organ modular platforms. The emerging economies such as China, Japan, India, and South Korea are also expecting to contribute to the growth of the organ-on-chip market in the region. The rise in disposable income, the growing number of clinical trials, and the rising investment in R&D activities are expected to propel the market growth.
Global Organ-on-chip Market Growth, by Region 2021-2027
Source: OMR Global
North America projected to Dominates the Organ-on-chip Market.
Geographically, North America is projected to dominate the organ-on-chip market and is estimated to maintain its dominance with a significant CAGR during the forecast period. The factors propelling the growth of the organ-on-chip market in the region include rising investment by public and private sectors, increasing toxicological testing of chemicals on the different types of organ cells, and technological advancement and their rapid adoption. Besides, the presence of pharmaceutical companies and key market players, availability of advanced organ-on-chip models, government support in form of funding, and awareness initiatives to promote organ-on-chip adoption also fueling the market growth.
Market Players Outlook
The key players in the organ-on-chip market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are MIMETAS B.V., BiomimX SRL, InSphero AG, Emulate, Inc., Hurel Corp., CN Bio Innovations, Ascendance Biotechnology, Inc., Nortis Inc., TissUse GmbH, Organovo Holdings, Inc, TARA Biosystems, Inc., among others. These market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, partnership collaboration, and geographical expansions so on. For instance, in August 2020, InSphero AG and ETH Zurich Bio Engineering Laboratory had a partnership collaboration for the commercialization of InSphero's Akura Flow organ-on-chip platform. It is a MPS designed to integrate 3D spheroid models for preclinical drug efficacy and toxicity testing applications under single- and multi-tissue organ networks.
The Report Covers
Market value data analysis of 2020 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global organ-on-chip market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.